Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia

The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. A major advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Langabeer, Stephen E., Faryal, Rehman, O'Dwyer, Michael, Loingsigh, Sorcha Ní
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125505/
https://www.ncbi.nlm.nih.gov/pubmed/32274226
http://dx.doi.org/10.1155/2020/9571691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125505/
https://www.ncbi.nlm.nih.gov/pubmed/32274226
http://dx.doi.org/10.1155/2020/9571691

Ejemplares similares